CATALOGUE / PT-141
PT-141 10MG
PT-141
Research peptide · Lyophilised powder in a sealed vial · for laboratory and research use only
Reagent specifications
| CAS number | 189691-06-3 (free base); 1607799-13-2 (acetate) |
|---|---|
| Molecular weight | 1025.2 g/mol (free base; PubChem reference value) |
| Storage | Sealed, dry and dark at −20 °C or colder; −50 to −80 °C for long-term storage |
| Certificate of analysis | Available on request · Request a COA |
CAS number and molecular weight are reference values for the compound identity, from PubChem. The salt form matters when comparing a formula or mass against a record.
Compound identity
| Compound class | Synthetic cyclic heptapeptide; melanocortin receptor agonist (α-MSH analogue) |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Sequence (one-letter) | Ac-Nle-c[DHfRWK]-OH (norleucine has no standard one-letter code; f = D-phenylalanine) |
| Molecular formula | C50H68N14O10 (free base, PubChem) |
| PubChem CID | 9941379 |
| Other names | Bremelanotide, PT 141 |
| Supplied as | Lyophilised powder, sealed vial |
| Quantity per vial | 10 mg |
| Intended use | Laboratory and research use only |
About PT-141
PT-141 is the development name for bremelanotide, a synthetic cyclic heptapeptide and an analogue of α-melanocyte-stimulating hormone (α-MSH). A lactam bridge between aspartic acid and lysine closes the ring: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.1 It is an agonist at several melanocortin receptors.
Titan Peptides supplies PT-141 as a lyophilised powder in a sealed 10 mg vial, for laboratory and research use only. It is a research chemical: not a drug, food or cosmetic, and not for human consumption.
Status in Australia
Bremelanotide is not named in the Poisons Standard June 2026 (F2026L00633),2 and it is not an approved therapeutic good in Australia. Research-grade PT-141 is a laboratory chemical. Our guide to research peptides and Australian law explains how the TGA treats unapproved peptide products.
Laboratory handling & storage
Keep the sealed vial dry, dark and frozen at −20 °C or colder (−50 to −80 °C for long-term storage), and let it reach room temperature in a desiccator before opening. PT-141 contains a tryptophan residue, one of the residues the storage literature flags for air oxidation and photo-oxidation, so limit its exposure to light and air. Solutions should be kept only briefly: split a reconstituted stock into single-use aliquots, freeze them and do not refreeze thawed material. See how to store peptides and reconstituting peptides with bacteriostatic or sterile water for the reasoning behind each step.
PT-141 quick answers
What form is PT-141 supplied in?
PT-141 is supplied as a lyophilised (freeze-dried) powder in a sealed vial containing 10 mg, for laboratory and research use only. It is a research chemical, not a drug, food or cosmetic, and is not for human consumption.
What is PT-141's CAS number?
The CAS number for bremelanotide free base is 189691-06-3, and the acetate salt has its own number, 1607799-13-2. PubChem (CID 9941379) lists the free base as C50H68N14O10 with a molar mass of 1025.2 g/mol, so the salt form matters when comparing a formula or mass against a record.
Is PT-141 the same compound as melanotan II?
No, although the two are closely related. They share the same cyclic seven-residue sequence, but melanotan II ends in a C-terminal amide and bremelanotide in a free carboxylic acid, a mass difference of about 1 g/mol. Low-resolution mass measurements can miss that gap, so identity work calls for high-resolution mass spectrometry or chromatography against a reference standard.
Is PT-141 legal in Australia?
Bremelanotide is not named in the June 2026 Poisons Standard and is not an approved therapeutic good in Australia. Research-grade PT-141 is supplied for laboratory and research use only; our guide to research peptides and Australian law sets out how the TGA treats unapproved peptide products.
Related catalogue items
References
- PubChem. Bremelanotide, CID 9941379. National Center for Biotechnology Information. Source
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (Standard for the Uniform Scheduling of Medicines and Poisons No. 48), F2026L00633. Commenced 1 June 2026. Federal Register of Legislation. Source